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burdens, i.e., HRQoL decrements, for the 31 conditions as mea-
sured by the EQ-5D US ranged from −0.002 to −0.195 on this
scale. Modeling disease-burden from other systems to the EQ-
5D US exhibited excellent ﬁt (R2 all > 0.85). When tested in
MEPS, the predicted disease-burdens in the EQ-5D US were
slightly biased (0.0012 from SF-6D(12), 0.0083 from EQ-5D
UK). Tested in USVEQ data, the predicted disease-burdens for
the EQ-5D US were more biased (0.0125 from HUI Mark 2,
0.0144 from HUI Mark 3). The standard deviation of differences
between predicted and actual disease-burdens was around 0.01
for most measures. CONCLUSION: This method produces rel-
atively unbiased estimates for disease-burden across HRQoL
scoring systems. Current error variance associated with this
method limits its usability. Future work should examine non-
linear cross-walks between HRQoL scores.
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WITH COLON CANCER AND ITS TREATMENT
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OBJECTIVES: To elicit preferences for the spectrum of health
states associated with Stage III colon cancer (CRC) and to
explore the effect of neuropathy associated with current stan-
dard of care for adjuvant treatment. METHODS: We inter-
viewed CRC patients and clinicians, developed health states and
used time trade-off (TTO) to elicit preferences from a conve-
nience sample of CRC patients and community members. We
elicited preferences for 7 health states: remission (REM); adju-
vant therapy with no (ADJ_NO), mild (ADJ_MLD), moderate
(ADJ_MOD), and severe (ADJ_SEV) neuropathy; metastatic
stable (MET_ST); and metastatic progressive (MET_PR) disease.
Each subject valued a randomly selected subset of 5 health states.
T-tests were used to test for differences in preferences. RESULTS:
Mean ages of the 49 patients and 49 community members were
60.6 and 59.8 years, respectively. 51% and 57% were male,
respectively. Mean TTO values (95% CIs) for patients/commu-
nity members were: REM 0.87 (0.81, 0.93)/0.83 (0.77, 0.89);
ADJ_NO 0.67 (0.55, 0.80)/0.62 (0.50, 0.74); ADJ_MLD 0.65
(0.49, 0.82)/0.52 (0.39, 0.65); ADJ_MOD 0.58 (0.40, 0.76)/0.48
(0.35, 0.61); ADJ_SEV 0.48 (0.30, 0.65)/0.35 (0.22, 0.49);
MET_ST 0.46 (0.30, 0.62)/0.54 (0.42, 0.65); MET PR 0.38
(0.21, 0.56/0.21 (0.09, 0.34). Signiﬁcant differences were
observed for both groups between TTO for REM and adjuvant
health states and between ADJ_NO and metastatic health states
(p < 0.04), except for ADJ_NO vs. MET_S within the patient
group. There was a non-signiﬁcant trend for patients to place a
higher TTO value on all health states than community members
(p = 0.20). CONCLUSION: These ﬁndings highlight the trade-
offs between the disutility of adjuvant treatment (particularly
with moderate to severe neuropathy) and the higher utility of
remission, and the severe utility loss during metastatic disease.
The preference values obtained from this study will be useful for
informing cost-utility analyses of treatment through progression
of colon cancer.
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OBJECTIVES: To identify theoretical and methodological chal-
lenges to valuing children’s health for cost-utility or beneﬁt-
cost analysis. METHODS: We reviewed the most common
approaches, quality-adjusted life years and willingness-to-pay
values, for valuing health in economic evaluations and consid-
ered methodological and practical issues associated with mea-
suring child health using each framework. RESULTS: The review
of theoretical and practical challenges suggests that both areas
pose challenges to valuing child health. Practical challenges
include elicitation issues and the consideration of household
effects of child illness. One challenge is the inability of young
children to value changes in health directly and the potential
biases associated with using proxy respondents. The most appro-
priate elicitation method will vary by age of the child under con-
sideration. Another key challenge arises from the status of
children not as independent economic actors, but as being depen-
dent on others for care and decision making. In addition, illness
in children may also affect parent/caregiver quality-of-life further
complicating the measurement of value associated with the
change in a child’s health status. From a theoretical perspective,
“value of a child’s health” has not yet been adequately deﬁned
if one accepts that many children are insufﬁciently mature to
have informed, considered preferences over health states. CON-
CLUSION: Recommendations for moving the ﬁeld forward in
valuing child health for economic evaluations will vary by age;
a “one size ﬁts all” approach does not readily ﬁt. Future research
should focus on minimizing bias from proxy respondents, con-
sideration of a family or household-based approach to valuing
health effects, and development of generic instruments for chil-
dren with age-appropriate domains.
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OBJECTIVE: Appropriate utilization of diabetes medications is
key to improving clinical and ﬁnancial effects of the disease.
Pharmacy beneﬁts may contain barriers to patients utilizing these
medications. This study assessed the impact of elimination of
member cost share and other beneﬁt barriers on utilization of
diabetes medications. METHODS: Study used a pre-post com-
parison of 1281 individuals whose pharmacy beneﬁts were pro-
vided by an employer that eliminated beneﬁt barriers (member
cost, reﬁll restrictions, prior authorization) on 1/1/2006. Eligible
study participants had continuous eligibility for pharmacy ben-
eﬁts from 1/1/2005 through 12/31/2006 and ﬁlled prescriptions
for diabetes medication both before and after the beneﬁt design
change date. Adherence to therapy was measured by a weighted
average of the therapeutic class Medication Possession Ratio
(MPR) and was calculated during the period prior to the beneﬁt
change (January 1, 2005–December 31, 2005) and following it
(January 1, 2006–December 31, 2006). RESULTS: Study popu-
lation was 45% female (mean age 46.6). Subsequent to beneﬁt
design change, MPR increased by 2.0% (78.2% to 80.2%; p-
value = 0.003) for core diabetic therapy (insulin, sulfonylureas,
metformin or combinations). Proportion of members with
optimal adherence (80% or more MPR) increased from 58.6%
to 64.9% (p-value < 0.001). Average number of prescriptions per
member did not change (11.7 vs. 11.7; p-value = 0.95), but days
supply increased signiﬁcantly (362 days vs. 459 days; p-value <
0.001) with no detectable increase in mail utilization. Proportion
of members using adjunct therapy (glucosidase inhibitors, amylin
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& GLP-1 analogs) in addition to core therapy increased signiﬁ-
cantly from 4.6% to 10.2% (p-value < 0.001), primarily due to
increased use of Byetta®. CONCLUSIONS: Removal of phar-
macy beneﬁt barriers improves an individual’s ability to achieve
optimal adherence to diabetes medication and thereby achieve
clinical goals. In conditions such as diabetes where optimal
therapy adherence has signiﬁcant implications, one should con-
sider decreasing or removing member cost share and other
beneﬁt barriers.
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OBJECTIVES: Racial disparities in diabetics exist in diabetes
control, as well as complications associated with diabetes. Such
disparities could lead to difference in likelihood of emergency
room (ER) visit among different races. This study examined the
association between patients’ race and ER in type 2 diabetes
patients newly starting oral antidiabetic therapy. METHODS:
This was a retrospective cohort study of Medicaid patients with
type-2 diabetes newly starting oral antidiabetic medication (met-
formin, sulfonylureas, thiazolidinediones). A cohort of type 2
diabetes patients was identiﬁed using ICD-9 code (250.xx) and
1 NDC code for antidiabetic medication. Information for demo-
graphic factors (race, age of patient, gender of the patient), clin-
ical factors (severity of diabetes, number of comorbidities),
medication related factors (number of medications consumed),
and access to care (number of diabetes related physician visits)
was extracted from the database. Patients’ race was categorized
as African Americans, Whites and Others. An ER visit was mea-
sured as a categorical dichotomous variable. Patients were fol-
lowed up for one year after the start date of new medication.
Multiple logistic regressions for three cohorts was performed to
assess the association patients’ race and likelihood of ER visit
adjusting for above mentioned factors. RESULTS: Among met-
formin users (n = 215), there was no difference in the likelihood
of ER visit between races. Among sulfonylureas users (n = 1171),
African Americans were associated with 51% increased likeli-
hood of ER visit as compared to whites (OR: 1.51, 95% CI:
1.14–2.0). Among thiazolidinedione users (n = 1751), there was
no difference in the likelihood of ER visit between races. Number
of medications and comorbidities were signiﬁcant predictors in
each of the analyses. CONCLUSION: Racial differences among
sulfonylureas users should be further investigated to understand
if there are disparities in other factors such as patients’ adher-
ence to sulfonylureas’ contributing to differences in ER use
between races.
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TREATMENT EFFECT ESTIMATION:A COMPARISON
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STRUCTURE MODEL AND DOUBLY ROBUST METHODS
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OBJECTIVES: To examine whether results from two small ran-
domized controlled trials (RCTs) converge with the results from
a large observational study with causal effect methods (OSCEMs)
in comparing the treatment effects of 2 insulin regimens, and to
compare different causal effect methods including propensity
score (PSM), marginal structure model (MSM) and doubly robust
methods (DRM). METHODS: We ﬁrst theoretically examined
the similarity and difference as well as pros and cons of RCT and
OSCEM approaches in TE estimation. Then, 2 RCTs (n = 105
and 97; crossover at 16th weeks) and 3 large OSCEMs (n = 4519,
in 4 post-baseline quarters, propensity score, marginal structural
model and doubly robust methods) were conducted to examine
whether the differences of treatment effect between 2 insulin reg-
imens estimated through RCTs converge with the differences of
the same treatment effect estimated through 3 OSCEMs. The
treatment effect was deﬁned as the reduction of hemoglobin A1c
(HbA1c) among patients with type 2 diabetes. The 2 insulin reg-
imens were once-daily basal analog insulin (QDBAI)—glargine
vs. twice-daily premixed analog insulin (BIDMAI)—lispro mix
75/25. RESULTS: Theoretically, RCTs have higher internal valid-
ity and lower external validity compared to OSCEMs. The dif-
ferences of HbA1c reductions between BIDMAI and QDBAI in
4 quarters estimated through 2 RCTs were similar to the differ-
ences estimated through 3 OSCEMs (RCTs: −0.39—p = 0.02, 
−0.38—p = 0.03 vs. OSCEMs: −0.48—p < 0.01, −0.72—p = 0.12,
−0.31—p = 0.11). CONCLUSION: Compared to OSCEMs,
RCTs may have higher internal validity, but lower external valid-
ity. With correct exercises, the results of OSCEMs and RCTs can
converge. OSCEMs are larger sample methods that may have
better external validity, but require a large sample size. Compared
to PSM, MSM and DRM are less efﬁcient, may require an even
larger sample size.
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RESULTS: CLINICAL PRACTICE VERSUS GUIDELINES
Huse D, Bizier R, Durden ED
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OBJECTIVES: The American Diabetes Association recommends
hemoglobin A1c tests be repeated within 3 months following an
above target result or a change in therapy. Our objective is to
examine how the frequency of retesting in clinical practice com-
pares to this recommendation. METHODS: A database of clin-
ical laboratory results linked to health plan claims (MarketScan
Lab) was used to identify patients receiving oral antidiabetic
therapy. Patients’ ﬁrst A1c test result between July 1, 2003 and
June 1, 2005 was classiﬁed as at target (less than 7), above target
(7–9), or poorly controlled (>9). The sample was restricted to
patients who had 6 months of claims histories prior to and after
the index test. Prescription drug claims were examined to iden-
tify therapy changes, deﬁned as adding a new medication or dis-
continuing one previously prescribed. Occurrence of A1c tests
within 6 months was assessed. RESULTS: 4836 patients were
identiﬁed, including 2450 (51%) who were at target, 1567
(32%) above target, and 819 (17%) poorly controlled. A1c
retesting occurred in 39.8% of patients with poor control,
35.6% of those above target, and 34.7% of those at target (p =
0.03). Among patients whose therapy was changed, retesting
occurred in 44.4% of those with poor control, 43.7% of those
above target, and 39.4% of those at target (p = 0.28). Rates of
retesting were higher among patients with commercial insurance
versus Medicaid, but the rate for poorly-controlled patients rel-
ative to those at target did not differ signiﬁcantly by insurance
status. CONCLUSION: There is little variation in the frequency
of retesting among diabetic patients at different A1c levels.
Retesting is more likely when patients change therapy; nonethe-
less a high proportion fails to be retested within 6 months. Clin-
ical practice has a long way to go to catch up with current A1c
testing guidelines, with implications for optimal treatment in
Type 2 diabetes.
